A research initiative called ANTHOLOGY is working to improve early diagnosis, treatment and quality of life for patients with amyloid transthyretin (ATTR) amyloidosis, including ATTR cardiomyopathy (ATTR-CM), according to a paper recently published in the journal Cardiology and Therapy.
Early diagnosis is crucial because starting treatment early can stop the disease from getting worse, improve quality of life and help patients live longer. Yet many patients experience delays in diagnosis due to unrecognized signs and symptoms.
By collecting and analyzing real-world data, ANTHOLOGY aims to improve early detection and optimize treatment for ATTR amyloidosis patients worldwide.
“This knowledge will be used to define world-class patient care, improve treatment outcomes and HRQoL [health-related quality of life], inform updates to clinical practice guidelines and treatment pathways, and transform ATTR amyloidosis management through evidence aimed at improving the quality of the current standard of care,” the study’s authors noted.
Read more about ATTR-CM treatment and care
ANTHOLOGY consists of two major studies: OverTTuRe and MaesTTRo. OverTTuRe will analyze past patient data from various sources, while MaesTTRo will track patients’ data in real-time using patient-reported outcome questionnaires, electronic health records and insurance claims.
The OverTTuRe study aims to understand the characteristics of patients with ATTR amyloidosis, how they are treated and their health outcomes. It also looks at how patients use healthcare services and how the disease affects their quality of life. Additionally, the study will examine healthcare use before patients are diagnosed.
The MaesTTRo study focuses on understanding patients’ medical history, treatment patterns and how well current treatments work in real-life settings. It also compares different treatments and their effectiveness. Researchers will explore factors that may lead to disease progression and analyze healthcare costs.
The studies will take place in multiple countries to help researchers understand how ATTR amyloidosis is managed in different regions.
“Using high-impact real-world evidence generated by the OverTTuRe and MaesTTRo studies, ANTHOLOGY will help to define world-class patient care, accelerate diagnosis and access to the most clinically effective therapies, and consequently improve patient outcomes,” the authors said.
Sign up here to get the latest news, perspectives, and information about ATTR-CM sent directly to your inbox. Registration is free and only takes a minute.
